Skip to content
Search

Latest Stories

New 'Nimbus' Covid variant could trigger summer infection wave, experts warn

UKHSA data up to 1 June reveals that 6.1 per cent of those tested for Covid were positive

Experts Warn Nimbus (NB.1.8.1) May Trigger COVID Summer Wave

‘Nimbus’, is raising concerns among health experts

iStock

A new highly transmissible Covid variant, known as ‘Nimbus’, is raising concerns among health experts as cases rise sharply in parts of Asia and begin to appear in the UK. Official data shows that the strain, which has been labelled N.B.1.8.1, could drive a summer wave of infections due to its increased contagiousness and potential to evade immunity from earlier vaccinations or infections.

Cases detected in the UK

According to the UK Health Security Agency (UKHSA), 13 confirmed cases of the variant have already been recorded in England, and 25 British samples have been submitted to international databases since the end of March. However, experts say these figures likely underestimate the true spread, given the current limited Covid testing regime compared to the height of the pandemic.


UKHSA data up to 1 June reveals that 6.1 per cent of those tested for Covid were positive—the highest weekly figure for 2025. This marks a 7 per cent increase from the previous week and a 97 per cent rise compared to early March.

Rapid international spread

Nimbus, which is a descendant of the Omicron family of variants, has been linked to a spike in cases in China, Singapore, and Hong Kong. Globally, it now accounts for around 10.7 per cent of Covid infections, up from just 2.5 per cent a month earlier, according to the World Health Organisation (WHO).

The WHO has designated the variant as a ‘variant under monitoring’, which means it is being tracked for its potential impact but is not currently classified as a variant of concern.

Scientists warn of summer spike

British scientists are now warning that the new strain could fuel a rise in cases over the summer months, particularly as people become more socially active during the warmer weather.

Professor Lawrence Young, a virologist at Warwick University, said: “We are very likely to see a spike of infections over the next couple of months, possibly by later this month or in July. But it’s difficult to predict the level of this infection wave.”

He explained that population immunity from previous vaccinations or infections is likely waning, and unlike flu, Covid continues to spread in hot and humid weather. Laboratory studies also suggest that Nimbus is more efficient at infecting human cells and may have enhanced abilities to evade the immune system.

No evidence of increased severity

Despite its contagiousness, there is currently no indication that Nimbus causes more severe illness or higher mortality rates than earlier strains. However, experts caution that vulnerable groups—such as the elderly, people in care homes, and those with weakened immune systems—remain at risk of serious illness.

Data from the Office for National Statistics indicates that Covid contributed to just over 300 deaths in England during May 2025.

Symptoms and vaccine protection

The symptoms of the Nimbus variant appear to be consistent with those of previous Covid strains. These include fatigue, fever, sore throat and muscle aches.

There is currently no suggestion that the variant causes different or more severe symptoms. Moreover, scientists believe that existing Covid vaccines, reformulated to tackle Omicron and its descendants, should still offer protection against Nimbus.

UKHSA data shows that people who received a Covid booster last spring were 45 per cent less likely to require hospital treatment compared to those who remained unvaccinated.

Who is eligible for the vaccine?

In the UK, free Covid vaccinations are currently being offered to:

  • Adults over the age of 75
  • Residents and staff in care homes
  • Individuals with weakened immune systems

The UKHSA has urged all eligible people to take up the vaccine offer to help protect themselves and others from severe illness, particularly with the rising presence of the Nimbus strain.

Officials closely monitoring situation

Dr Gayatri Amirthalingam, deputy director at UKHSA, confirmed that the agency is closely tracking the spread of the N.B.1.8.1 variant both domestically and internationally.

“UKHSA is monitoring all available data relating to SARS-CoV-2 variants in the UK and abroad, and we continue to publish our findings in our regular Flu and Covid-19 surveillance reports,” she said.

“NB.1.8.1 has been detected in small numbers in the UK to date, but international data suggests that it is growing as a proportion of all Covid-19 cases.”

As the summer approaches, experts are reminding the public that even though the pandemic is no longer dominating daily life, Covid continues to evolve. The emergence of Nimbus underscores the need for vigilance, particularly among those at higher risk.

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
Serena Williams

Williams explained that her weight challenges began after the birth of her first daughter

Getty Images

Serena Williams says GLP-1 made her feel light physically and mentally after 31lb loss

Highlights:

  • Serena Williams reveals she has lost more than 31lbs using a GLP-1 medication
  • The tennis legend says the treatment enhanced her existing healthy lifestyle
  • She stresses that weight loss should not change self-image or self-confidence

Serena Williams has revealed she has lost more than 31lbs after turning to a weight-loss medication, saying the treatment has transformed both her body and her mindset.

The 23-time Grand Slam champion, 43, told PEOPLE that using a GLP-1 medication — a type of injection that works by regulating appetite — has helped enhance the healthy lifestyle she already maintained through diet and exercise.

Keep ReadingShow less
Monica Seles

Seles first began noticing symptoms around five years ago

Getty Images

Tennis champion Monica Seles reveals living with myasthenia gravis

Highlights:

  • Nine-time Grand Slam winner Monica Seles diagnosed with myasthenia gravis three years ago
  • The 51-year-old revealed her condition ahead of this month’s US Open to raise awareness
  • Disease causes muscle weakness and has no known cure

Former world number one Monica Seles has revealed she was diagnosed with myasthenia gravis, a rare neuromuscular autoimmune disease, three years ago. The 51-year-old, who won nine Grand Slam singles titles, went public ahead of the US Open to raise awareness of the condition, which causes muscle weakness and can affect multiple parts of the body.

Symptoms and diagnosis

Seles first began noticing symptoms around five years ago when she experienced double vision and struggled with coordination. “I would be playing [tennis] with some kids or family members, and I would miss a ball. I was like, ‘Yeah, I see two balls,’” she told the Associated Press. These symptoms eventually led to her diagnosis, which took time for her to come to terms with.

Keep ReadingShow less